|
BQS-Bundesauswertung
2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mammachirurgie |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Qualitätsindikatoren |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Qualitätsindikator
9: Indikation zur brusterhaltenden Therapie |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Qualitätsziel: |
|
|
Angemessene Indikationsstellung zur
brusterhaltenden Therapie bei Frauen mit |
|
|
|
|
|
|
|
|
|
|
|
|
Tumorstadium pT1 oder pT2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grundgesamtheit: |
|
Gruppe 1: |
Alle Frauen mit Primärerkrankung und invasivem
Mammakarzinom |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
im Stadium pT1 oder pT2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gruppe 2: |
Alle Frauen mit Primärerkrankung und invasivem
Mammakarzinom im Stadium pT1 |
|
|
|
|
|
|
|
|
Gruppe 2a: |
Alle Frauen mit Primärerkrankung und invasivem
Mammakarzinom im Stadium pT1 |
|
|
|
|
|
|
|
|
|
|
|
ohne präoperative tumorspezifische Therapie |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gruppe 3: |
Alle Frauen mit Primärerkrankung und invasivem
Mammakarzinom im Stadium pT2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kennzahl-ID: |
|
|
Gruppe 2: |
2006/18n1-MAMMA/46212 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Referenzbereich: |
|
Gruppe 2: |
>= 60% - <= 85% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gesamt 2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gruppe
1 |
|
|
Gruppe
2 |
|
|
Gruppe
2a |
|
|
Gruppe
3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frauen mit brust- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
erhaltender Therapie |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
bei gegebener |
|
|
|
36.433 / 49.617 |
|
23.851 / 28.833 |
|
22.650 / 27.078 |
|
12.673 / 20.971 |
|
|
|
Indikation |
|
|
|
|
|
|
73,43% |
|
|
|
82,72% |
|
|
|
83,65% |
|
|
|
60,43% |
|
|
|
Vertrauensbereich |
|
|
|
|
|
|
|
82,28% - 83,16% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Referenzbereich |
|
|
|
|
|
|
|
|
>= 60% - <= 85% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frauen ohne |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
brusterhaltende |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Therapie (auf Wunsch |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
der Frau, trotz |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
erfüllter Kriterien zur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
brusterhaltenden |
|
|
|
|
806 / 49.617 |
|
|
378 / 28.833 |
|
|
362 / 27.078 |
|
|
429 / 20.971 |
|
|
|
Therapie) |
|
|
|
|
|
|
1,62% |
|
|
|
1,31% |
|
|
|
1,34% |
|
|
|
2,05% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gesamt 2005¹ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gruppe
1 |
|
|
Gruppe
2 |
|
|
Gruppe
2a |
|
|
Gruppe
3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frauen mit brust- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
erhaltender Therapie |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
bei gegebener |
|
|
|
33.226 / 46.472 |
|
21.576 / 26.542 |
|
20.387 / 24.811 |
|
11.722 / 20.100 |
|
|
|
Indikation |
|
|
|
|
|
|
71,50% |
|
|
|
81,29% |
|
|
|
82,17% |
|
|
|
58,32% |
|
|
|
Vertrauensbereich |
|
|
|
|
|
|
|
80,82% - 81,76% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
¹ |
Die neu berechneten Ergebnisse weichen von
der Bundesauswertung 2005 ab, da die Rechenregeln für die Grundgesamtheit
modifiziert wurden. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Verteilung der Krankenhausergebnisse
[Diagramm 9, Kennzahl-ID 2006/18n1-MAMMA/46212]: |
|
|
|
|
|
|
Anteil von Frauen mit brusterhaltender
Therapie an allen Frauen mit Primärerkrankung und |
|
|
|
|
|
|
invasivem Mammakarzinom im Stadium pT1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 Krankenhäuser haben keinen Fall in dieser
Grundgesamtheit. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Krankenhäuser mit mindestens 20 Fällen in
dieser Grundgesamtheit: |
|
|
|
|
|
|
|
|
|
|
|
|
Minimum - Maximum der Krankenhausergebnisse:
42,9% - 100,0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Median der Krankenhausergebnisse: 83,7% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Krankenhäuser |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
417 Krankenhäuser haben mindestens 20 Fälle in
dieser Grundgesamtheit. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Krankenhäuser mit weniger als 20 Fällen in
dieser Grundgesamtheit: |
|
|
|
|
|
|
|
|
|
|
|
|
Minimum - Maximum der Krankenhausergebnisse:
0,0% - 100,0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Median der Krankenhausergebnisse: 84,6% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Krankenhäuser |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 Krankenhäuser haben weniger als 20 Fälle
in dieser Grundgesamtheit. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
© BQS 2007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29. Juni 2007 / 2006 - D5350-L40722-P20628 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|